WaveMan
WaveMan · Company
IONS · Ionis Pharmaceuticals Inc
> Search tickers & screens ⌘K
LIVE
← All companies

IONS Ionis Pharmaceuticals (IONS) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0000874015
Quote by TradingView
Form 144 · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
269
13F, latest reported quarter
Conversions, 180 days
26
Codes C/M, not in net · $14.4M priced

What the filings say about IONS

Insiders, 180 days
-$25.6M net sold
1 buyer · 12 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$59.7K
1 notice

Ionis Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, IONIS PHARMACEUTICALS INC insiders sold a net $25.6M of stock across 329 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-29.

Insider
Filed
Shares
Value
Since filing
Devers Shannon L.
EVP, Chief Human Resources Ofc
SELL
2026-10-19 SECtraded 2026-10-16
1,357
$59.1K
-3.2%
Context
  • 16 earlier Form 4 trades (code P or S) here by this insider (16 sales), the last on Apr 2, 2026.
  • The trade is 7.6% of the 17,811 shares held after it.
  • 1 other insider sold within 30 days.
  • 269 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Human Resources Ofc Devers Shannon L. sold about $59.1K of IONS on Oct 16, 2026; 1 other insider sold within 30 days and 269 funds added in the latest 13F quarter.
Swayze Eric
EVP Research
SELL
2026-10-19 SECtraded 2026-10-16
53
$2.3K
-3.2%
Context
  • 31 earlier Form 4 trades (code P or S) here by this insider (31 sales), the last on Jun 25, 2026.
  • The trade is 13.6% of the 390 shares held after it.
  • 1 other insider sold within 30 days.
  • 269 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP Research Swayze Eric sold about $2.3K of IONS on Oct 16, 2026; 1 other insider sold within 30 days and 269 funds added in the latest 13F quarter.
Hayden Michael R
Director
BUY
2026-07-31 SEC
5,000
$258.0K
-19.3%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Jul 30, 2026.
  • +14.7% median (+14.7% mean) 90-day return after 2 previous buys.
  • The trade is 20.8% of the 24,000 shares held after it.
  • No other insider bought within 30 days.
  • 269 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Hayden Michael R bought about $258.0K of IONS on Jul 31, 2026; 269 funds added in the latest 13F quarter.
Hayden Michael R
Director
BUY
2026-07-31 SECtraded 2026-07-30
15,000
$800.7K
-19.3%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on May 1, 2025.
  • +14.7% median (+14.7% mean) 90-day return after 2 previous buys.
  • The trade is 78.9% of the 19,000 shares held after it.
  • No other insider bought within 30 days.
  • 269 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Hayden Michael R bought about $800.7K of IONS on Jul 30, 2026, the largest insider purchase at the company on our record; 269 funds added in the latest 13F quarter.
BENNETT C FRANK
EVP, Chief Scientific Officer
SELL
2026-07-09 SECtraded 2026-07-07
5,536
$462.7K
-24.5%
Context
  • 24 earlier Form 4 trades (code P or S) here by this insider (24 sales), the last on Mar 3, 2026.
  • The trade is 7.4% of the 75,018 shares held after it.
  • 9 other insiders sold within 30 days.
  • 269 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Scientific Officer BENNETT C FRANK sold about $462.7K of IONS on Jul 7, 2026; 9 other insiders sold within 30 days and 269 funds added in the latest 13F quarter.
329 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 324 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$25.6M over 180 days
+$997.3K over 90 days
below 90% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
269 funds bought in last quarter
more than 94% of Pharma & Biotech
Revenue
+33.8% year over year
more than 71% of Pharma & Biotech
Margin
-40.4% net margin
more than 52% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
12.5% of the float short (float per yahoo 2026-10-27) · 7.7 days to cover · settled 2026-10-15
more than 80% of Pharma & Biotech
The situation: each line is one rule over one dataset
3 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Oct 19EVP, Chief Human Resources Ofc Devers Shannon L. sold $59.1K (Oct 16)
Oct 19EVP Research Swayze Eric sold $2.3K (Oct 16)
Oct 16Officer Devers Shannon L. filed to sell $59.7K by Oct 16 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch IONS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-38.0%12M
-40%-19%+1%+22%2025-102025-122026-022026-042026-062026-082026-10 2026-03-16 · HOUGEN ELIZABETH L sold $14.9M2026-03-09 · Monia Brett P sold $8.9M2026-03-03 · BENNETT C FRANK sold $5.7M2026-01-30 · Monia Brett P sold $5.2M2026-05-04 · LOSCALZO JOSEPH sold $4.5M2026-02-02 · BENNETT C FRANK sold $4.0M2026-06-26 · Monia Brett P sold $4.0M2026-01-16 · Monia Brett P sold $3.3M2026-03-03 · Diaz Allene M. sold $3.1M2026-06-12 · Kordasiewicz Holly B. sold $3.0M2025-10-31 · Geary Richard S sold $2.6M2025-10-31 · Geary Richard S sold $2.6M2026-02-06 · Monia Brett P sold $2.5M2025-11-19 · HERMAN JOAN E sold $2.3M2026-01-07 · Devers Shannon L. sold $2.2M2026-06-26 · Schneider Eugene sold $2.1M2025-12-01 · WENDER JOSEPH H sold $1.7M2026-06-25 · Monia Brett P sold $1.7M2026-02-02 · BENNETT C FRANK sold $1.7M2026-03-10 · Jenne Kyle sold $1.6M2026-04-01 · KLEIN JOSEPH III sold $1.5M2025-10-31 · Geary Richard S sold $1.5M2026-06-12 · Kordasiewicz Holly B. sold $1.5M2026-01-02 · Swayze Eric sold $1.5M2025-11-06 · Geary Richard S sold $1.4M2026-02-02 · BENNETT C FRANK sold $1.4M2025-11-25 · Devers Shannon L. sold $1.4M2026-05-04 · LOSCALZO JOSEPH sold $1.3M2026-03-10 · Monia Brett P sold $1.3M2026-07-07 · BENNETT C FRANK sold $1.3M2026-03-10 · Monia Brett P sold $1.2M2026-03-10 · Jenne Kyle sold $1.2M2025-10-31 · LOSCALZO JOSEPH sold $1.2M2026-03-03 · Diaz Allene M. sold $1.2M2026-06-24 · Monia Brett P sold $1.1M2026-03-03 · Devers Shannon L. sold $1.1M2025-11-06 · Geary Richard S sold $1.1M2026-03-03 · KLEIN JOSEPH III sold $1.1M2026-03-03 · BENNETT C FRANK sold $1.0M2026-01-16 · HOUGEN ELIZABETH L sold $972.0K2026-07-01 · KLEIN JOSEPH III sold $902.6K2025-11-19 · HERMAN JOAN E sold $865.6K2026-10-16 · Devers Shannon L. filed to sell $59.7K2026-07-07 · BENNETT C FRANK filed to sell $5.7M2026-07-07 · Diaz Allene M. filed to sell $863.6K2026-07-07 · Kordasiewicz Holly B. filed to sell $108.5K2026-07-01 · KLEIN JOSEPH III filed to sell $910.4K2026-06-26 · Baroldi Mariana filed to sell $451.7K2026-06-26 · Schneider Eugene filed to sell $3.9M2026-06-26 · O'NEIL PATRICK R. filed to sell $245.5K2026-06-25 · Swayze Eric filed to sell $839.3K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns IONS: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
24,631,956 sh
$2.0B
Capital World Investors
21,669,226 sh
$1.7B
BlackRock, Inc.
10,704,660 sh
$848.8M
VANGUARD PORTFOLIO MANAGEMENT LLC
7,859,529 sh
$623.2M
WELLINGTON MANAGEMENT GROUP LLP
7,651,415 sh
$606.7M

Congress trades in IONS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

IONS planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Devers Shannon L.
Filed 2026-10-16
$59.7K
BENNETT C FRANK
Filed 2026-07-07
$5.7M
Diaz Allene M.
Filed 2026-07-07
$863.6K
Kordasiewicz Holly B.
Filed 2026-07-07
$108.5K
KLEIN JOSEPH III
Filed 2026-07-01
$910.4K

IONS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Horizon Kinetics Medical ETF
$864.6K position · as of 2026-06-30
4.5%
Tweedy, Browne International Value Fund
$138.2M position · as of 2026-06-30
3.2%
Artisan Small Cap Fund
$28.4M position · as of 2026-06-30
3.0%
Tweedy, Browne Value Fund
$13.5M position · as of 2026-06-30
2.8%
AlphaCentric Life Sciences and Healthcare Fund
$1.2M position · as of 2026-06-30
2.6%
Eventide Healthcare & Life Sciences Fund
$45.6M position · as of 2026-06-30
2.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
56 registered trials, 20 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
7
Phase 1
2 active
17
Phase 2
1 active
20
Phase 3
12 active
7
Not applicable
1 active
5
Multi-phase
4 active
What changed recently
REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome
2026-09-30 · Recruiting → Active Not Recruiting
Phase 3
Zilganersen Expanded Access Program for Individuals With Alexander Disease
2026-09-30 · Available → Approved For Marketing
,
CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Childre
2026-09-29 · Not Yet Recruiting → Recruiting
Phase 3
PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodyna
2026-09-16 · Completion moved 2027-02 → 2027-04
PHASE1,PHASE2
CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study
2026-09-15 · Completion moved 2026-03 → 2026-03-13
,
CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study
2026-09-15 · Active Not Recruiting → Completed
,
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Dr. Monia
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$12.5M
$14.2M
$2.7M
-16%
+19%
2022
$7.3M
$9.6M
$2.8M
-37%
+14%
2021
$13.3M
-$2.6M
$3.8M
-50%
+26%
2020
$11.0M
$3.4M
$5.5M
-6%
+26%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $25.6M sold by insiders over 180 days, 269 funds added last quarter, $59.7K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

IONS financials

Revenue growth
+33.8%
XBRL, annual
Net margin
-40.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$874.1M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-64.7%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$560.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
4.00x
long-term 2025-12-31 (6 months older than the period end) plus current 2025-12-31 (6 months older than the period end); equity 2026-06-30
Cash flow to debt
-0.28x
TTM operating cash flow over long-term 2025-12-31 (6 months older than the period end) plus current 2025-12-31 (6 months older than the period end)
Return on equity
-105.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-18.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-24.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$8.7B
market value at close 2026-10-27 on 2026-07-23 shares, plus long-term 2025-12-31 (6 months older than the period end) plus current 2025-12-31 (6 months older than the period end), minus cash 2026-06-30
FCF yield
-7.7%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$943.7M$705.1M$787.6M$587.4M
Operating income-$381.7M-$475.1M-$353.7M-$410.2M
Net income-$381.4M-$453.9M-$366.3M-$269.7M
EPS (diluted)-2.38-3.04-2.56-1.90
Operating cash flow-$268.6M-$500.9M-$307.5M-$274.4M
Cash$372.3M$242.1M$399.3M$276.5M
Long-term debt$1.3B$1.2B$1.2B$1.2B
Buybacksn/an/an/a$0
SEC XBRL, fiscal years, as known on 2026-10-29

IONS Stock Sonar score 6/7 axes

Find similar shapesCompare

IONS ranks highest on institutional and government (81st percentile) and growth (71st), and lowest on insider conviction (32nd), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
56
Inputs
  • Return on equity-105.5% · 31 pct, sector of 545
  • Return on assets-18.9% · 67 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-24.9% · 70 pct, sector of 576
Financial health
34
Inputs
  • Debt to equity4.00x · 5 pct, sector of 352
  • Cash flow to debt-0.28x · 63 pct, sector of 371
Growth
71
Inputs
  • Revenue growth, YoY+33.8% · 71 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
32
Inputs
  • Net Form 4 buying (codes P and S), 180d-$25.6M · 8 pct, sector of 429
  • Insider buyers, 180d1 · 56 pct, sector of 438
Institutional and government
81
Inputs
  • Funds adding, latest quarter269 · 94 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$760K · 68 pct, sector of 133
Risk and compliance
33
Inputs
  • Short interest, % of float+12.5% · 32 pct, sector of 816
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+13.8% · 34 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

IONS filings, in plain words

Are Ionis Pharmaceuticals insiders buying or selling IONS?

In the 180 days to 2026-10-29, Ionis Pharmaceuticals insiders were net sellers, a net $25.6M: $1.1M of purchases and $26.6M of sales reported on Form 4, by 1 buyer and 12 sellers.

Are there planned insider sales of IONS?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-29, covering $59.7K of stock; the latest, by Devers Shannon L., was filed 2026-10-16.

Read the full summary

In the 180 days to 2026-10-29, Ionis Pharmaceuticals insiders were net sellers of IONS, a net $25.6M across purchases and sales reported on Form 4 by 1 buyer and 12 sellers. Sales outweighed purchases more than tenfold by value. None of the 23 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-29, covering $59.7K of stock. Each figure is counted from SEC and House filings as of 2026-10-29, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies